Ligand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity. - Wikidata - wikimedia - TriplyDB

Ligand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity.

Ligand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity.

http://www.wikidata.org/entity/Q27682260

about

Editorial of Special Issue Ruthenium Complex: The Expanding Chemistry of the Ruthenium Complexes An Organometallic Compound which Exhibits a DNA Topology-Dependent One-Stranded Intercalation Mode Hydrogen bonding and anticancer properties of water-soluble chiral p-cymene Ru(II) compounds with amino-oxime ligands Synthesis and anticancer activity of carbosilane metallodendrimers based on arene ruthenium(ii) complexes Design, synthesis and characterisation of new chimeric ruthenium(II)-gold(I) complexes as improved cytotoxic agents.In vitro and in vivo evaluation of water-soluble iminophosphorane ruthenium(II) compounds. A potential chemotherapeutic agent for triple negative breast cancer Allosteric cross-talk in chromatin can mediate drug-drug synergy.Expression proteomics study to determine metallodrug targets and optimal drug combinations.In vivo evaluation of small-molecule thermoresponsive anticancer drugs potentiated by hyperthermia.Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer Stereochemical control of nucleosome targeting by platinum-intercalator antitumor agents.Application of imaging mass spectrometry approaches to facilitate metal-based anticancer drug research.Inhibition of cancer cell growth by ruthenium complexes Fighting Cancer with Transition Metal Complexes: From Naked DNA to Protein and Chromatin Targeting Strategies.Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity.A ruthenium anticancer compound interacts with histones and impacts differently on epigenetic and death pathways compared to cisplatin.Atomistic-level portrayal of drug-DNA Interplay: a history of courtships and meetings revealed by molecular simulations.DNA or protein? Capillary zone electrophoresis-mass spectrometry rapidly elucidates metallodrug binding selectivity.Fingerprinting the junctions of RNA structure by an open-paddlewheel diruthenium compound.Ruthenium(ii) p-cymene complexes of a benzimidazole-based ligand capable of VEGFR2 inhibition: hydrolysis, reactivity and cytotoxicity studies.Is matching ruthenium with dithiocarbamato ligands a potent chemotherapeutic weapon in oncology?Metal-based drugs that break the rules.Regulating the anticancer properties of organometallic dendrimers using pyridylferrocene entities: synthesis, cytotoxicity and DNA binding studies.Combining [arene-Ru] with azocarboxamide to generate a complex with cytotoxic properties.Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment.Visualization of metallodrugs in single cells by secondary ion mass spectrometry imaging.The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials.X-ray Structure Analysis of Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) Bound to Human Serum Albumin Reveals Two Ruthenium Binding Sites and Provides Insights into the Drug Binding Mechanism.Interaction of anticancer Ru(III) complexes with single stranded and duplex DNA model systems.The Differential Distribution of RAPTA-T in Non-Invasive and Invasive Breast Cancer Cells Correlates with Its Anti-Invasive and Anti-Metastatic Effects.Single-molecule kinetics and footprinting of DNA bis-intercalation: the paradigmatic case of Thiocoraline.Tuning the cytotoxicity of ruthenium(ii) para-cymene complexes by mono-substitution at a triphenylphosphine/phenoxydiphenylphosphine ligand.Structural analysis of ruthenium-arene complexes using ion mobility mass spectrometry, collision-induced dissociation, and DFT.Upconverting Nanoparticles Prompt Remote Near-Infrared Photoactivation of Ru(II)-Arene Complexes.Nucleosome acidic patch-targeting binuclear ruthenium compounds induce aberrant chromatin condensation.Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action† †Electronic supplementary information (ESI) available: Experimental, crystallographic, biological and mass spectrometric data, full list of pr Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action.Protein metalation by metal-based drugs: X-ray crystallography and mass spectrometry studies.Interfering with DNA High-Order Structures using Chiral Ruthenium(II) Complexes.An Organoruthenium Anticancer Agent Shows Unexpected Target Selectivity For Plectin.

P2860

Q26782380-C2712957-E277-44AE-A28D-787AE5A4AB75 Q27704876-019EE7F8-AE0C-4BD4-B128-A1CF30923C88 Q28834484-5043E8AA-7C04-4D8B-8223-3AEAAE8F79E5 Q30358389-5317B044-9B5A-4564-A1A4-816AE1DFF0E1 Q30380707-8512F65B-EA15-4B1F-B3A6-D452689F3794 Q30398565-AA903BE5-9FD5-42C2-BC8B-7A2CD913F6B7 Q30843868-5E8A8F56-76F6-40BD-809B-6D40BB2427C3 Q33685955-C2B31CBA-100E-4B3F-9162-69C4D842A546 Q33847893-199C77A2-92EF-4CBE-9F76-6DC4144C8EA4 Q35757208-941FA632-C05F-4BF7-BFEC-7D401D2F69F6 Q35770597-ADDD23EE-03FA-4B49-B9C1-6303A3D39B4F Q36268494-A9F534E2-4780-4554-A51C-B0E5AAB90371 Q36574799-B7E7890A-6D7B-48DA-AE1D-A22380B18202 Q37337277-748D5569-F2E4-4A2F-A892-B06234D510EC Q37657640-2C6A4CA7-12F2-43CB-B883-1984433F6125 Q37709331-A3CEB2D5-6DEC-4453-A017-A1DC54FEFC4C Q38237566-86608914-B640-4486-8059-42CEE44A58B7 Q38287806-59B46665-8F43-4F5B-AD2D-127EB5D1FB50 Q38344386-03FB9094-96DD-4164-8DA8-27C6629FCBCF Q38699445-C836A040-EBD5-4FB5-A77E-2CCBEB9822E8 Q38710506-E6243979-F82E-40EB-B2FE-783F350A3BBD Q38714812-26C1D49E-6AC7-4BCF-BBBB-2FF1D7863EC7 Q38770155-1B9E8E51-6B54-4147-A65E-1F01329633AE Q38942212-F1A98E1E-31A7-497E-8A0E-BBC4EB1AA3EA Q39220891-C5290391-0BC0-46F8-A450-CA90FD8345D1 Q39309141-2612832A-8717-4DD1-B1DF-AEA773C5BFB3 Q39400527-CE1A00EB-392B-41A3-B287-A700040D0286 Q39753526-1409F424-3DB8-48C5-A787-4C565F0C4903 Q40759010-E937799B-E18E-423F-BAC9-5F45C2FC184E Q41661168-00697BF0-FCC1-4F42-89A4-EFBAA021EB86 Q43184421-40260BFC-33CD-4C9C-AB8D-473EBF0EAA75 Q46256422-ABE3DDA4-2CEC-47E4-89F8-0D27496BB0DD Q46595407-A8407C53-A0CF-47F9-9D3E-31B067DEF0DD Q46608566-CE6431D2-FDD1-48C0-A90C-490FEECE40C6 Q47152126-B8D9E6CB-164B-4A3E-929A-69A11F9F3CB2 Q47159745-8143F2E6-BC4E-4300-ACCE-EF309BD3B545 Q47196925-E6E77268-1B07-4CB2-870F-781FB88332E0 Q47667663-A99ABCDB-3131-4A73-BBE2-51345AF77303 Q48049650-92A75F90-87EB-4CF3-8CE3-34F011F8DB95 Q48088409-8153C28E-B604-4AD6-951D-04FAC00C62CC

P2860

Ligand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity.

http://www.wikidata.org/entity/Q27682260

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Ligand substitutions between r ...... eting and anticancer activity.

@ast

Ligand substitutions between r ...... eting and anticancer activity.

@en

Ligand substitutions between r ...... geting and anticancer activity

@nl

type

label

Ligand substitutions between r ...... eting and anticancer activity.

@ast

Ligand substitutions between r ...... eting and anticancer activity.

@en

Ligand substitutions between r ...... geting and anticancer activity

@nl

prefLabel

Ligand substitutions between r ...... eting and anticancer activity.

@ast

Ligand substitutions between r ...... eting and anticancer activity.

@en

Ligand substitutions between r ...... geting and anticancer activity

@nl

P1433

Q27682260-3F8A99BB-6F51-4B90-A707-3475E8EE1995

P1476

Q27682260-4A283ED4-C426-461F-9802-A607413A5495

P2093

Q27682260-1CDA244E-881D-48CB-88B6-D0CE67109BA8

Q27682260-274ADFC8-57FE-46C0-917B-C64CF1946641

Q27682260-596A4B4A-260F-4927-8B1B-BD6E6A6B9DDC

Q27682260-826951B0-6613-4FB2-AE9A-16252B8FBAA8

Q27682260-ABA9F7F9-F519-4A35-B6E2-C21D4867C37B

Q27682260-B94A5AF3-3B0D-4CA5-B320-781132AFD752

Q27682260-D5CA1027-DFCF-404A-B56B-6C570F03CF55

Q27682260-DE856FFA-A812-4CAF-BEF3-DE42F178EA13

P2860

Q27682260-03B4F7B7-9764-4BB6-A36B-7699C546914C

Q27682260-074088CE-0A81-458A-904B-AA21C698AD94

Q27682260-0DAE7E0B-F1EC-446F-9D2A-BA96451BDF7B

Q27682260-1478CBB5-B76C-4F17-804A-42CB35281DDF

Q27682260-161BD87D-AAC6-41F3-B4F5-4A3C60D370F0

Q27682260-165303B4-0075-4F09-92CD-8C3A4BA3E1B9

Q27682260-18F2D8D7-4F2F-4CD9-A8B0-55A4D429D90D

Q27682260-1F674EB9-29C8-4051-A9DB-51ACAA2FA53C

Q27682260-22D6B0D3-5F4C-4EC0-B76D-14A8C0DCDBB1

Q27682260-28981EC0-82D1-42C7-8ABA-0453CEDB8238

P2888

Q27682260-AD92372E-C14C-4962-AE79-80037AABF439

P304

Q27682260-EDB1DC72-860D-4A3C-A5FD-EE899BE0478C

P31

Q27682260-3D474924-45E1-44FE-99B2-E8B2F25C3EAC

P3181

Q27682260-74909B44-4E09-433A-8A73-FD46F945A3EF

P356

Q27682260-A066DE6D-8A6D-4F4D-8097-A385D5C96AB9

P407

Q27682260-E42E71C5-73A1-40C6-AB82-60A0DD7126F8

P478

Q27682260-A8D5EBC3-BCB4-4EFC-B83F-0014605203D3

P50

Q27682260-53019117-BFE3-469E-A46A-A037814CC08A

Q27682260-62D92DD8-5C75-4181-8ED2-434184BCEAA2

Q27682260-EE7F7B22-90A1-4036-BA4B-0C15E2581CCD

Q27682260-EFF433A2-93DD-4120-B956-4030F3472F5B

Q27682260-FB3C582A-AF85-402E-9911-F4FAE8C9AA64

P577

Q27682260-7DF1C980-24E5-4EEA-A8C7-B94F651922C3

P5875

Q27682260-2B0020A4-CDDB-4E32-9ADB-8E08DF10B786

P6179

Q27682260-9C246453-AA29-463E-8738-06A3C4D37D2E

P698

Q27682260-D08218FD-8E52-4444-93C0-9122F36DACA2

P932

Q27682260-3E3BDB7C-BF00-42CE-BDFB-6E68287FD4FC

P3181

P356

P1433

Nature Communications

P1476

Ligand substitutions between r ...... eting and anticancer activity.

@en

P2093

Catherine M Clavel

http://www.w3.org/2001/XMLSchema#string

Charmian Hui Fang Yeo

http://www.w3.org/2001/XMLSchema#string

Curt A Davey

http://www.w3.org/2001/XMLSchema#string

Gabriela E Davey

http://www.w3.org/2001/XMLSchema#string

Pablo Campomanes

http://www.w3.org/2001/XMLSchema#string

Peter Dröge

http://www.w3.org/2001/XMLSchema#string

Ursula Rothlisberger

http://www.w3.org/2001/XMLSchema#string

Zenita Adhireksan

http://www.w3.org/2001/XMLSchema#string

P2860

A decade of exploring the cancer epigenome - biological and translational implications

Density-functional thermochemistry. III. The role of exact exchange

Generalized Gradient Approximation Made Simple

Comparison of simple potential functions for simulating liquid water

Solvent mediated interactions in the structure of the nucleosome core particle at 1.9 a resolution

DNA stretching and extreme kinking in the nucleosome core

Site selectivity of platinum anticancer therapeutics

DNA stretching in the nucleosome facilitates alkylation by an intercalating antitumour agent

A ruthenium antimetastasis agent forms specific histone protein adducts in the nucleosome core

Specific DNA structural attributes modulate platinum anticancer drug site selection and cross-link generation

P2888

P304

3462

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1502013

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NCOMMS4462

http://www.w3.org/2001/XMLSchema#string

P407

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Alexey A. Nazarov

Michael Groessl

P577

2014-03-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260874777

http://www.w3.org/2001/XMLSchema#string

P6179

1043505532

http://www.w3.org/2001/XMLSchema#string

P698

24637564

http://www.w3.org/2001/XMLSchema#string

P932

3959212

http://www.w3.org/2001/XMLSchema#string